NEW TARGET-DIRECTED PT-PORPHYRIN ANTICANCER DRUGS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$46,000.00
Award Year:
1987
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
7117
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Andrulis Research Corp
7315 Wisconsin Ave Suite 650n, Bethesda, MD, 20814
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PAUL SCHWARTZ PHD
(301) 657-1700
Business Contact:
() -
Research Institution:
n/a
Abstract
THE OBJECTIVE OF THIS PROJECT IS TO IMPROVE THE SELECTIVITY OF ACTION OF PLATINUM ANTITUMOR AGENTS. PLATINUM COMPOUNDS HAVE SHOWN ACTIVITY IN MANY TYPES OF TUMORS, BUT SEVERE DOSE-LIMITING SIDE EFFECTS HAVE AFFECTED THEIR CLINICAL UTILITY. BY DIRECTING THESE AGENTS MORE SPECIFICALLY TO TUMOR SITES, THEIR EFFECTIVENESS SHOULD BE IMPROVED. THE APPROACH USED TO ACHIEVE THIS IMPROVED SPECIFICITY WILL BE TO LINK THEM TO SYNTHETIC PORPHYRINS THAT ARE KNOWN TO HAVE TUMORLOCALIZING PROPERTIES. PLATINUM COMPLEXES HAVING KNOWN ANTITUMOR ACTIVITY WILL BE CHEMICALLY REACTED WITH SUBSTITUTED TETRAPHENYLPORPHYRIN COMPOUNDS. THE REACTION CONDITIONS WILL ASSURE STABLE BINDING OF THE ACTIVE PT MOIETY TO THE SUBSTITUENT SITES ON THE PORPHYRIN RING RATHER THAN AT THE CENTRAL SITE. IN THISWAY, THE PORPHYRIN THAT ACCUMULATES IN TUMOR TISSUE CAN ACT AS A CARRIER TO THE TUMOR FOR THE ACTIVE PT SPECIES. THE SUCCESS OF THIS PROGRAM WILL LEAD TO NEW, MORE SPECIFIC ANTITUMOR AGENTS, A MAJOR GOAL IN THE DESIGN OF NEW DRUGS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government